CANTRAIN · Host-pathogen interaction systems as tools to identify antifungal targets in C. Albicans and C. Dubliniensis
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2005-03-01 → 2009-02-28
- EU contribution
- €2,689,991
- Participants
- 12
- Scheme
- RTN
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - CANTRAIN (Host-pathogen interaction systems as tools to identify antifungal targets in C. Albicans and C. Dubliniensis)
1. We have bridged the gap between environmental stimuli inducing infection mechanism and the signal transduction pathways triggered by these stimuli. We have characterised a G protein-coupled receptor that is important for the yeast-to-hyphae transition on solid medium. Currently, we are characterising the pathway by which this receptor triggers this morphogenesis. In this aspect, we have recently identified a genetic interaction between the phosphodiesterases and this receptor, a phenotype that does not occur in Saccharomyces cerevisiae. We have also characterised the CaSPS-sensing pathway, a pathway by which amino acids induce their own uptake or induce the expression of a number of proteases. 2. Several potential new targets for antifungal drug discovery in both C. albicans and C. dubliniensis have been identified. These include the fungal specific phosphodiesterase Pde2, the trehalose-6-phosphate phosphatase Tps2, various components of the SPS sensing system, the AUF genes, which are genes belonging to one family that are upregulated during adhesion on human tissue. 3. In order to find these novel targets and also in order to characterise the pathways involved, we have developed proteomics and transcriptome analysis under various conditions. These include in vitro, ex vivo and in vivo host-pathogen interaction systems. One example is a newly developed in vivo biofilm system using a subcutaneous rat model system. This analysis also includes a comparative genomics approach comparing C. albicans and C. dublinienis. Two important differences that we have observed are the role of methionine for morphogenesis in these two species and the different substrate specificities of the potassium transporters. Finally, novel reporter constructs and a C. albicans specific two-hybrid system have been developed. 4. Apart from the pathogen, we have also looked at the host site in order to understand the reaction of the host upon an infection. Both macrophage and dendritic cell systems have been investigated and the results have been submitted for publication. 5. We have also developed different screening assays in order to screen for novel antifungal drugs. An example of a screening system is based on the G protein-coupled receptor Gpr1 that we mentioned above. A deletion of this receptor results in sensitivity to a low concentration of histatin 5, a naturally occurring antifungal. We are using a wild type strain in the presence of histatin 5 to find compounds that inhibit the growth, which are possible antagonists of this Gpr1 protein. We have also developed novel types of screening for antifungal compounds where in one screen, the antifungal efficacy as well as toxicology for human cells can be determined. Training part Apart from the biannual workshops were all the ESR and ER students presented their results, we have also organised several training courses in which most of them participated. These include: - real time PCR course; - in vitro biofilm course; - host-pathogen interaction of C. albicans using human epithelial models; - bioinformatics and microarray analysis course o C. albicans - macrophage interaction course; - microarray analysis / bioinformatics; - antifungal drug screening using robotics; - FEBS advanced practical and lecture course. Potential applications CANTRAIN will provide the pharmaceutical industry with new, partially validated antufungal targets and for some targets already lead compounds. In addition, CANTRAIN will provide trained personnel to carry out these tasks in the industry or in academia. Novel technologies, such as proteome and microarray analyses during host-pathogen interactions will also be developed.
Data: CORDIS, © European Union
Project objective
One of the major tasks the Life Science industry faces in the coming years is to validate a plethora of targets for treatment of various diseases and the identification of novel lead compounds to generate novel pharmaceutics specifically acting on the targets identified. CanTrain" will train both early and experienced researchers in the methodologies necessary for drug development, including target identification, target validation, development of cell-based screening assays all of which is caused by fungal pathogens, especially strategies for the identification of novel antifungal drugs. Fungal infections have increased largely in the recent years, mostly due to immuno- compromised patients in intensive care units.Despite intensive therapy, a high proportion of these patients contract systemic mycosis. CanTrain attempts to establish approaches leading to the development of novel anti-fungal compounds by combining the expertise of 11 partners in cellular sensor systems and signalling pathways controlling morph ogenesis and virulence, model systems for host-pathogen interaction, assay development and drug screening technologies. This network will not only give insight into mechanisms of host-pathogen interactions in general, but also bridge the gap between the identification of potential target proteins from the pathogen required for colonisation and infection of the host. CanTrain will enable the identification of antifungal compounds by establishing intelligent cell-based screening assays considering the host environment.These cell-based screening assays will employ reporter genes activated by signalling pathways required for pathogenesis. The experimental approaches of CanTrain comprise state-of-the-art technologies, including global transcriptome and proteome analysis of pathogens during the infection process using in vitro host-pathogen tissue systems."
Original text from CORDIS.
Participants
- FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY VZW · ZWIJNAARDECoordinatorBelgium
- COMENIUS UNIVERSITY IN BRATISLAVA · BRATISLAVA 16City levelSlovakia
- EMC MICROCOLLECTIONS GMBH · TUEBINGENGermany
- FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V.* · MÜNCHENGermany
- INSTITUTE OF PHYSIOLOGY, THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC · PRAGUECity levelCzechia
- LUDWIG INSTITUTE FOR CANCER RESEARCH - STOCKHOLM BRANCH · STOCKHOLMSweden
- MEDIZINISCHE UNIVERSITÄT WIEN · VIENNACity levelAustria
- STOCKHOLMS UNIVERSITET · StockholmSweden
- THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (HEREINAFTER CALLED TCD) · DUBLINCity levelIreland
- UNIVERSIDAD COMPLUTENSE DE MADRID · MADRIDSpain
- UNIVERSITA DEGLI STUDI DI MILANO · MILANOItaly
- UNIVERSITY OF MANCHESTER · MANCHESTERUnited Kingdom
Links
Data: CORDIS, © European Union
